Plasma p ‐tau ₂₁₇ as a suitable biomarker for monitoring cognitive changes in Alzheimer’s disease

Abstract

Background: With the approval of anti‐amyloid therapies in Alzheimer’s disease (AD), surrogate biomarkers are urgently needed to monitor treatment effects that translate into clinical benefits.

The paper